Escitalopram is the active ingredient in Lexapro, a prescription medicine labeled for adult major depressive disorder and generalized anxiety disorder. The selected FDA labeling describes common reactions, serious warnings, interactions, and important evidence gaps. It cannot determine whether the medicine suits you or caused a particular symptom.
Reading a medicine label can leave you with several different questions: what the names mean, which conditions are approved uses, and how to interpret findings that sound reassuring or alarming. This guide focuses on one selected Lexapro record and its oral tablets, rather than comparing antidepressants or explaining prescription changes. Its useful details include separate adult depression and anxiety trial findings, limitations in sexual-function reporting, and interactions supported by different kinds of evidence. Understanding those distinctions can make the information clearer without turning a general article into personal prescribing advice.
Which escitalopram product does this guide describe?
This guide describes Lexapro film-coated tablets for oral use containing escitalopram as escitalopram oxalate. Product identity matters when reading Medication Guide safety information or interpreting a Lexapro comparison with another antidepressant. Those names describe different aspects of a medicine, not several separate active ingredients.
Lexapro is the brand name. Escitalopram names the active ingredient, while escitalopram oxalate identifies its salt form in this product. Film-coated oral tablet describes the dosage form. The selected record's description section also describes an oral solution but states that it is not currently marketed. That is a statement within this record, not an independent check of present-day availability. The record does not assign different adult indications to the tablets and solution.
Escitalopram is the S-enantiomer of racemic citalopram. In plain language, it is one particular mirror-image molecular form within the related compound. This chemical relationship does not establish interchangeable prescriptions, equivalent doses, identical approvals, or superior benefit.
The source is application NDA021323, SPL ID 9ff46a66-0f97-4a78-9d18-ec576f63bae7, set ID 13bb8267-1cab-43e5-acae-55a4d957630a. Its effective-time field is 20231001; its included Medication Guide separately says “Revised: 4/2024.” Neither makes this article a review of the latest labeling or every escitalopram product.
What adult uses and proposed action does the label describe?
The two labeled adult uses are major depressive disorder, or MDD, and generalized anxiety disorder, or GAD. These approvals also appear in the discussion of Lexapro's indications compared with Zoloft, but neither everyday sadness nor the broad word “anxiety” automatically identifies a labeled condition.
An indication names a condition for which the product is approved. It does not diagnose the person reading the label or establish that the medicine fits every experience described as depression or anxiety. The selected prescribing information identifies escitalopram as a selective serotonin reuptake inhibitor, or SSRI.
Reuptake is a process by which nerve cells take serotonin back up. The label says escitalopram's antidepressant action is presumed to relate to increased serotonin activity resulting from inhibition of that process. “Presumed” preserves uncertainty about how the antidepressant effect occurs. It does not establish that a particular person's symptoms reflect a demonstrated serotonin deficiency.
What do the adult side-effect findings actually establish?
The adult findings describe reactions observed in separate MDD and GAD study groups, not a personal forecast. The introductory Lexapro side-effect discussion provides broader context, while interpreting serious-risk information explains why a listed possibility is not an inevitable outcome.
In the adult MDD trials, prominent reactions included nausea, insomnia, increased sweating, fatigue, sleepiness, and ejaculation problems, primarily delayed ejaculation. The separate GAD trials also identified nausea, insomnia, fatigue, and ejaculation problems among prominent reactions, alongside decreased sexual desire and difficulty reaching orgasm. Different study populations do not show that having one diagnosis makes the medicine safer.
- Digestive findings included nausea, diarrhea, constipation, and indigestion.
- Sleep-related findings included both difficulty sleeping and sleepiness.
- Fatigue and increased sweating were documented, although they describe different experiences.
- Sexual-function findings included reduced desire, ejaculation difficulties, erection difficulties, and delayed or absent orgasm.
Sexual-function estimates have particular limits. The label acknowledges that people and clinicians may hesitate to discuss these experiences, so reported frequencies likely underestimate their occurrence. It also says adequately designed studies examining sexual dysfunction with escitalopram are lacking. Underlying psychiatric illness can itself affect sexual functioning, making timing and personal context important without proving either cause.
The following table compares evidence categories within this selected record, not medicines or diagnoses.
| Evidence in the selected Lexapro record | What it describes | What it does not establish |
|---|---|---|
| Adult MDD trials | Reactions observed among adults studied for major depressive disorder | Which reactions an individual will experience |
| Adult GAD trials | Findings from a separate generalized anxiety disorder population | That GAD makes treatment safer or less safe than MDD |
| Sexual-function reporting | Reported changes and acknowledged underreporting | A precise personal likelihood or the cause of every sexual difficulty |
| Controlled-trial weight findings | No clinically important body-weight difference between treatment groups | A guarantee against individual weight changes |
| Voluntary postmarketing reports | Events reported after approval | Reliable frequency estimates or proof of causation |
The weight findings illustrate why context matters. Controlled trials found no clinically important body-weight difference from placebo. Elsewhere, increased weight appears among other premarketing observations and decreased weight among postmarketing reports. These statements can coexist: an overall trial finding does not exclude an individual change, and a voluntary report cannot reliably establish frequency or causation.
Which warnings are different from common side effects?
Serious warnings concern potentially dangerous conditions, not simply more uncomfortable versions of common reactions. Understanding boxed warnings and serious-risk information adds context to the basic Lexapro safety overview, but the selected product's warnings provide the drug-specific evidence.
The boxed warning reflects increased suicidal thoughts and behaviors in younger patients in short-term antidepressant studies, including young adults aged 18 through 24. These were pooled antidepressant findings, not solely Lexapro trials. The label calls for attention to worsening symptoms and emerging suicidal thoughts or behavior at every adult age, especially early in treatment and around prescription changes.
Other warnings describe distinct problems. These explanations are not a checklist for diagnosing a reaction yourself:
- Serotonin syndrome is potentially life-threatening. It can involve changes in thinking or awareness, high temperature, muscle stiffness or twitching, and loss of coordination. It can occur with escitalopram alone, with greater risk from certain combinations.
- Mania or hypomania activation involves a marked change in mood, energy, or activity. In someone with bipolar disorder, antidepressant treatment may precipitate a mixed or manic episode.
- Low blood sodium can cause confusion, weakness, or unsteadiness and can become life-threatening in severe cases.
- Bleeding risk ranges from unusual bruising or nosebleeds to serious hemorrhage. Other medicines can add to this risk.
- Seizures have been reported during Lexapro treatment, and the label includes a specific seizure warning.
- Angle-closure eye problems can occur in susceptible people with anatomically narrow drainage angles. Eye pain, vision changes, or redness or swelling around the eye require prompt medical attention.
The Medication Guide directs immediate medical contact or emergency evaluation for suspected serotonin syndrome and urgent attention to new or worsening safety concerns. It also warns about discontinuation symptoms after abrupt stopping. This article supplies no medication-change instructions.
For immediate danger or a life-threatening emergency, call 911. For suicidal thoughts or crisis support, call or text 988, as described by NIMH. MVBH is not emergency care.
Why do escitalopram interactions extend beyond antidepressants?
Interactions can involve serotonin activity, blood clotting, heart rhythm, or another medicine's exposure in the body. The Lexapro interaction overview and guidance on reading product-specific warnings provide context, but these concerns have different explanations and cannot be reduced to one general warning.
The selected label contraindicates use with monoamine oxidase inhibitors, or MAOIs, because of serotonin-syndrome risk. This includes relevant nonpsychiatric treatments such as linezolid and intravenous methylene blue. Other serotonergic agents, including certain migraine medicines, opioids, and St. John's wort, can also increase serotonin-syndrome risk. This is not an exhaustive interaction list.
Aspirin, nonsteroidal anti-inflammatory drugs, antiplatelet medicines, and anticoagulants raise a different concern: they can add to bleeding risk. Their relevance does not depend on whether they treat a mental health condition.
Pimozide is also contraindicated. Importantly, the interaction discussion cites racemic citalopram findings involving increased pimozide concentrations and possible dangerous heart-rhythm effects. That is not an escitalopram-only trial. Separately, the counseling section states that citalopram and escitalopram should not be coadministered.
Another study found that escitalopram increased desipramine's peak concentration and total exposure. Desipramine is processed through an enzyme pathway called CYP2D6. The label expressly says the clinical significance of this measured finding is unknown. A change in drug exposure is meaningful evidence, but it does not by itself establish what symptoms or harm a particular person will experience.
What can this label not tell an individual adult?
The label cannot predict individual benefit, tolerability, or safety. Neither Medication Guide risk language nor comparisons between antidepressants removes the limits of who was studied, which conditions were excluded, or how the findings apply outside a trial.
In the older-adult discussion, about 69 of 1,144 escitalopram-treated participants were aged 60 or older. The label considers that insufficient to adequately assess age-related differences in safety or effectiveness. Its larger racemic-citalopram population is separate evidence, not additional escitalopram participants. Older adults also have a separately identified concern about greater susceptibility to low sodium.
People with seizure disorders were excluded from premarketing clinical studies, and Lexapro was not systematically evaluated in that population. Recent myocardial infarction and unstable heart disease were also generally excluded and not systematically evaluated. Severe renal impairment has pharmacokinetic and chronic-treatment evidence gaps. Limited evaluation is neither proof of safety nor proof that harm is inevitable.
A healthy-volunteer study found no impairment on intellectual and motor-performance measures under its study conditions. Nevertheless, the label retains caution about driving and hazardous machinery because psychoactive medicines may affect judgment, thinking, or movement. That study cannot clear every treated adult to drive.
Treatment remains individual. NIMH's psychotherapy overview explains that treatment planning should reflect personal needs and medical circumstances under professional guidance. Psychotherapy may be used alongside medication or as another treatment option. A prescription label informs that broader plan without deciding it.
Written by Tim Francis, SUD Content Specialist. This article is educational and does not provide diagnosis or individual prescribing instructions.
Frequently asked questions
Does escitalopram oxalate mean a different active medicine?
In this selected Lexapro product, escitalopram names the active ingredient and escitalopram oxalate names its salt form. Lexapro is the brand, and film-coated oral tablet describes the dosage form. These terms describe different aspects of the same selected product; they do not identify several separate active medicines.
Does the oral-solution description prove it is available now?
No. The selected record describes an oral solution while expressly stating that it is not currently marketed. This article attributes that statement to the record rather than claiming an independent present-day availability check. The record also does not establish different adult indications for its tablet and solution descriptions.
Can the MDD and GAD tables tell me which patients tolerate it better?
Not reliably. The tables summarize reactions in separate study populations with different treatment contexts. They help describe what was observed, but differences between them do not establish that a diagnosis itself makes escitalopram safer or easier to tolerate. Neither table predicts an individual adult's experience.
Does a listed reaction prove escitalopram caused my symptom?
No. A listed event does not settle the cause of an individual's symptom. Some findings come from controlled trials, while others are voluntary reports with uncertain frequency and causation. Sexual difficulties, for example, can relate to treatment or underlying psychiatric illness. Serious or rapidly worsening symptoms still need timely medical attention.
Why does the Lexapro label discuss citalopram research?
Escitalopram is a particular molecular form within racemic citalopram, and the selected label includes some related-compound evidence. Its pimozide discussion and part of its older-adult discussion identify citalopram findings. Those findings must not be relabeled as escitalopram-only studies, and the molecular relationship does not establish prescription interchangeability.
